NCT02935465

Brief Summary

The overarching aim of this project is to conduct a randomized controlled study to determine whether Mindfulness-Oriented Recovery Enhancement (MORE) vs. a Support Group (SG) can improve pain regulation and hedonic functions (i.e., natural reward responsiveness) thought to be governed by the endogenous opioid system among opioid-treated, chronic, non-neuropathic back pain patients (CNBP) and thereby improve clinical pain, affect, and opioid use.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 11, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 17, 2016

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
Last Updated

March 6, 2020

Status Verified

March 1, 2020

Enrollment Period

2.7 years

First QC Date

October 11, 2016

Last Update Submit

March 4, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Changes in endogenous opioid system function in response to pain challenge

    PET opioid receptor binding potential from baseline through pain challenge

    Change from week 0 to 8 weeks

  • Changes in fMRI activity level during natural reward processing

    Blood oxygen dependent signal (BOLD) response during viewing and regulating response to natural reward cues measured during a fMRI scan.

    Change from week 0 to 8 weeks

Secondary Outcomes (3)

  • Pain sensitivity as a measure of volume of hypertonic saline

    Change from week 0 to 8 weeks

  • Self-report affect ratings

    Change from week 0 to 8 weeks

  • Significant correlation between PET and fMRI measures with improvements in clinical pain, affect, and opioid use

    Change from week 0 to 8 weeks

Study Arms (2)

Mindfulness-Oriented Recovery Enhancement

EXPERIMENTAL

Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.

Behavioral: Mindfulness-Oriented Recovery Enhancement (MORE)

Support Group

ACTIVE COMPARATOR

Participants will attend a support group weekly for eight weeks.

Behavioral: Support Group

Interventions

Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.

Mindfulness-Oriented Recovery Enhancement
Support GroupBEHAVIORAL

A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.

Support Group

Eligibility Criteria

Age21 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • age 21-60 years of age
  • English fluency
  • /20 vision with corrective lenses
  • current chronic, non-neuropathic back pain diagnosis determined by physician assessment
  • reporting pain ≥3 on 0-10 scale with opioid medication
  • current use of prescription opioids for ≥3 consecutive months
  • ability to understand study procedures and to comply with them for the entire length of the study

You may not qualify if:

  • Mindfulness experience (e.g., MBSR or shamatha/vipassana meditation)
  • psychosis
  • untreated, active suicidality in the past month
  • and severe non-opioid substance use disorder in the past year as assessed with the MINI
  • clinically unstable illness judged to interfere with treatment, and presence of facial/jaw pain
  • pregnancy
  • inability or unwillingness of individual to give written informed consent
  • physical characteristics that preclude neuroimaging or study procedures (e.g., metal implants, etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

College of Social Work

Salt Lake City, Utah, 84112, United States

Location

MeSH Terms

Conditions

Bronchiolitis Obliterans Syndrome

Interventions

Self-Help Groups

Condition Hierarchy (Ancestors)

Organizing PneumoniaBronchiolitis ObliteransBronchiolitisBronchitisBronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesGraft vs Host DiseaseImmune System Diseases

Intervention Hierarchy (Ancestors)

OrganizationsHealth Care Economics and Organizations

Study Officials

  • Eric L Garland, PhD

    The University of Utah

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Director of Integrative Medicine in Supportive Oncology and Survivorship, Huntsman Cancer Institute; Associate Dean for Research and Associate Professor, College of Social Work

Study Record Dates

First Submitted

October 11, 2016

First Posted

October 17, 2016

Study Start

September 1, 2016

Primary Completion

June 1, 2019

Study Completion

June 1, 2019

Last Updated

March 6, 2020

Record last verified: 2020-03

Locations